FL-WAX
Metasaurs , one of the fastest-growing NFT communities in the world, and WAX ($3.5B market cap), the most utilized blockchain in the world for games, processing three-quarters of all game-related transactions daily, announced a ground-breaking partnership to bring new world-class P2E (play-to-earn) games to the WAX ecosystem.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211122006228/en/
The creators of Metasaurs and founders of WAX will be co-founding a new NFT gaming studio, MetaGames to develop new game projects including the official Metasaurs Game and the launch of the RAWR token to be released in Q1 2022.
Since its inception in 2017, WAX has been coined “The King of NFTs,” but it’s so much more. WAX’s vIRL® technology is leading the future of digital commerce and it is the #1 blockchain by transaction volume in the world. It currently has more than 8M monthly users and is growing 400k+ users per month.
The WAX gaming-optimized blockchain processes 15 million transactions per day and is the #2 layer-1 blockchain behind only Ethereum in daily and 30 day NFT sales volume. Alien Worlds, one of the most popular games in the world, is built on the WAX blockchain, and independently boasts a $2.3B market cap for its own in-game economy.
"The foundation of WAX was built on gaming,” said William E. Quigley, co-founder of WAX, “and the official Metasaurs Game is the perfect use case for a play-to-earn gaming franchise created on WAX, taking advantage of our high volume transaction capacity, unique fee structure of no minting and gifting transaction fees, and energy efficient and low carbon footprint.”
Metasaurs are Dinosaur-Bored Ape hybrids of the popular Bored Ape Yacht Club NFT. The extended storyline, based on Dr. DMT, creating the Metasaurs, unlocks endless creative potential with regard to future games, avatars, and other multi-media on the WAX platform and across the emerging metaverse.
"It is our mission to create fun games which will share their economies with the lifeblood of the community—the players—rather than siphoning all value only to the publishers,” said Merlin Kauffman, creator of Metasaurs. ”Blockchain technology is best suited for this use-case, and we are excited to partner with WAX to create differentiated gaming experiences for the mass market."
“Merlin is a grassroots thought-leader in the NFT space,” said Quigley. “His track record building one of the most passionate fastest-growing NFT communities combined with our deep knowledge of NFT gaming economies put us in a privileged position to co-create the official Metasaurs Game. Our gaming studio, MetaGames, has all the right ingredients to create a series of successful play-to-earn gaming franchises.”
Quigley continued, “As we spend an increasing amount of time virtually than ever before, NFTs pave a way for users to have a stake in these new applications and digital worlds. WAX is at the forefront of this gaming evolution in the way we live online, building tools in a way that benefits everyone involved.”
About Metasaurs
The genesis Metasaurs collection is 9,999 NFTs created by Dr. DMT in The Lab from 300+ hand-drawn traits, each Metasaur consists of between 4-7 combined traits, of various rarities. Dr. DMT is authentic BAYC Ape #4588, and he is constantly developing new formulas to expand the Metasaurs experiment. The possibilities are endless, like the infinite lifespans of these Metasaurs on the blockchain .
About WAX - The King of NFTs
The Worldwide Asset eXchange ™ (WAX), aka the King of NFTs, is the world’s #1 blockchain, as measured by number of users and transactions, according to Dappradar.com. WAX’s mission is to bring NFTs to the mass market in the safest, most secure, environmentally friendly, and easy-to-use marketplace in the world. WAX is also the leading entertainment NFT network — in 2018, WAX introduced vIRLs® , giving consumer product companies the ability to directly link NFTs to physical consumer products.
About MetaGames Studio
Creators of world-class games, we are building the future of play-to-earn gaming experiences on the WAX blockchain. Co-founded by William Quigley, Merlin Kauffman, and Ben Bindell in 202, with initial studio development of the official Metasaurs Game and RAWR token to be released in Q1 2022. MetaGames ’ mission is to build branded social gaming communities that share their economies with the players, rather than siphoning all of the value only to the game publishers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211122006228/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 07:05:00 CET | Press release
L’Oréal to acquire an additional 10% stake in Galderma recognizing its scientific leadership in dermatology and long-term growth potential Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additio
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 04:37:00 CET | Press release
The Challenge: Deepfakes undermine both the accuracy and fairness of AI face detection due to variations in human features.The Technology: Ant International’s AI model uses a novel ‘Mixture of Experts’-based Adversarial Debiasing approach to achieve superior fairness and accuracy across diverse demographics.The Impact: This advancement strengthens payment security, offering robust protection against deepfake fraud and enhancing eKYC compliance globally. Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the Nati
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom